Compare Morgan Stanley (MS) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Morgan Stanley vs Repligen Corporation Common Stock — how do they compare? Morgan Stanley trades at $181.59 (market cap $293.13B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Morgan Stanley is far larger — about 26.3× Repligen Corporation Common Stock's market cap, and Morgan Stanley pays a 2.46% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Morgan Stanley for 90 Days and Repligen Corporation Common Stock for 0 Days on average.
| MS | RGEN | |
|---|---|---|
Market Cap | $293.13B | $11.14B |
Volume | 8,184,975 | 1,259,263 |
Sector | Financials | Health |
52-Week High | $228.42 | $194.57 |
52-Week Low | $154.37 | $102.87 |
Typical Hold Time | 90 Days | 0 Days |
Enterprise Value | $658.86B | $11.02B |
Dividend Yield | 2.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Morgan Stanley (MS) trades at $190.02, showing stability with no recent price change. The stock exhibits a bearish technical signal but maintains strong fundamentals, with revenue growing to $66.0B in 2025 and net income reaching $16.9B. Recent earnings have consistently beaten expectations, and analyst consensus remains bullish with a $229.25 price target. The company highlights growth in wealth management and AI financing as key drivers.
The outlook for MS is positive, supported by earnings momentum and strategic growth areas, though risks include volatile cash flows and high debt levels. Investment opportunity lies in its above-sector profitability and analyst upside, but investors should monitor macroeconomic sensitivity and competitive pressures in financial services.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
